VDCR as a treatment option for refractory or relapsed multiple myeloma in Bortezomib pretreated patients, a single center experience

被引：0
|
作者：
Dobrosch, L. [1 ]
Hahn-Ast, C. [1 ]
Mayer, K. [1 ]
von Lilienfeld-Toal, M. [1 ]
Brossart, P. [1 ]
Janzen, V [1 ]
机构：
[1] Univ Klinikum Bonn, Med Klin 3, Bonn, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P543
引用
收藏
页码：162 / 162
页数：1
相关论文
共 50 条
  • [21] Update on the Treatment of Heavily Pretreated, Relapsed Refractory Multiple Myeloma
    Valdes, Rodriguez
    ONCOLOGY-NEW YORK, 2020, 34 (11): : 504 - 507
  • [22] BORTEZOMIB IN MULTIPLE MYELOMA: TREATMENT AND RETREATMENT. A SINGLE CENTER EXPERIENCE
    Warzocha, Krzysztof
    Kraj, Maria
    Poglod, Ryszard
    Kwasniak, Beata
    ACTA POLONIAE PHARMACEUTICA, 2008, 65 (06): : 753 - 756
  • [23] Bortezomib in multiple myeloma: Treatment and retreatment. A single center experience
    Bilalis, Antonios G.
    Papadimitriou, Konstantinos
    Pouli, Anastasia
    Papanastasiou, Konstantinos
    Tsakanikas, Seraphem
    Stefanitsi, Panagiota
    Sioni, Anastasia
    Koropoulis, Georgios
    Stamatelou, Marina
    BLOOD, 2007, 110 (11) : 279B - 279B
  • [24] IMPACT OF BORTEZOMIB IN THE SURVIVAL OF PATIENTS WITH REFRACTORY OR RELAPSED MULTIPLE MYELOMA WITH RENAL FAILURE. EXPERIENCE OF A SINGLE CENTRE
    Parrilla Agustin, Carreno
    Belen, Hernandez Ruiz M.
    Primo Carmen, Calle
    Eliana, Olazo
    Elisa, Pereira
    Luis, Piccone
    Alberto, Martinez-Calero
    Javier, Nieto
    Isabel, Ferreras
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 : 424 - 424
  • [25] Bortezomid in association therapy in relapsed, refractory multiple myeloma: Experience of a single center
    Buquicchio, C.
    Iacobazzi, A.
    Tarantini, G.
    Ciuffreda, L.
    Desantis, G.
    Santorsola, D.
    Riezzo, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 151 - 151
  • [26] Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma
    Jimenez-Zepeda, Victor H.
    Reece, Donna E.
    Trudel, Suzanne
    Chen, Christine
    Tiedemann, Rodger
    Kukreti, Vishal
    LEUKEMIA & LYMPHOMA, 2013, 54 (03) : 555 - 560
  • [27] Bortezomib asociated to dexamethasone in patients with relapsed/refractory multiple myeloma
    de la O, G. M. Maria
    Garcia-Delgado, R.
    Cuesta, M. A.
    Garrido, P.
    Dominguez, B.
    Hernandez, F.
    Galan, M.
    Sanchez, A.
    Garcia-Sanchez, R.
    Lopez, E.
    Perez, E.
    Bailen, A.
    Heiniger, A. I.
    Ramirez, G.
    Garcia, A.
    Jurado, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 482 - 483
  • [28] Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma
    Richardson, Paul G.
    Badros, Ashraf Z.
    Jagannath, Sundar
    Tarantolo, Stefano
    Wolf, Jeffrey L.
    Albitar, Maher
    Berman, David
    Messina, Marianne
    Anderson, Kenneth C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 150 (04) : 428 - 437
  • [29] Bortezomib in relapsed or refractory myeloma patients
    Leonetti Crescenzi, S.
    Piccioni, A. L.
    Bagnato, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 208 - 208
  • [30] A single-center treatment sequencing analysis in patients with relapsed/refractory multiple myeloma (RRMM)
    Kumar, Swarup
    Clark, Jackson
    Alvarez-Soto, Alvaro
    El Warrak, Samantha
    Kumar, Shruthi
    Braish, Julie
    Reddy, Aswanth
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S190 - S191
12345